HeartFlow’s AI breakthrough predicts heart attacks with 5x higher accuracy
Heartflow, Inc. has presented groundbreaking data at the American Heart Association (AHA) Scientific Sessions 2025. The findings validate the use of TPV-based staging, measured with Heartflow Plaque Analysis, as a predictor of future heart attacks or cardiovascular death.
Heartflow's AI-driven platform transforms coronary CTA images into personalized 3D heart models. It provides actionable insights into plaque location, volume, and composition, and its impact on blood flow. Results from the DECIDE Registry showed that this technology led to significant changes in medical management for over half of patients, with an average LDL cholesterol reduction of 18.7 mg/dL at 90 days.
The FISH&CHIPS Study, involving nearly 8,000 symptomatic patients, found that those with the highest total plaque volume (TPV) stage had more than a 5x greater risk of major cardiovascular events compared to those in the lowest stage. This was independently associated with increased rates of cardiovascular death and myocardial infarction over a median 3.3 years of follow-up.
With over 1,400 institutions globally adopting Heartflow and validation through over 100 studies, the technology is transforming coronary artery disease management. It enables early detection, accurate diagnosis, and lifelong management, redefining precision cardiovascular care. Heartflow's coronary CTA image acceptance rates exceed 96%, demonstrating high accuracy and reproducibility in real-world practice.
